Cargando…
Bortezomib inhibits Burkitt's lymphoma cell proliferation by downregulating sumoylated hnRNP K and c-Myc expression
Bortezomib (Velcal) was the first proteasome inhibitor to be approved by the US Food and Drug Administration to treat patients with relapsed/refractory multiple myelomas. Previous studies have demonstrated that bortezomib inhibits tumor cell proliferation and induces apoptosis by blocking the nuclea...
Autores principales: | Suk, Fat-Moon, Lin, Shyr-Yi, Lin, Ren-Jye, Hsine, Yung-Hsin, Liao, Yen-Ju, Fang, Sheng-Uei, Liang, Yu-Chih |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4694880/ https://www.ncbi.nlm.nih.gov/pubmed/26317903 |
Ejemplares similares
-
Paralogs hnRNP L and hnRNP LL Exhibit Overlapping but Distinct RNA Binding Constraints
por: Smith, Sarah A., et al.
Publicado: (2013) -
hnRNP A1 and hnRNP F Modulate the Alternative Splicing of Exon 11 of the Insulin Receptor Gene
por: Talukdar, Indrani, et al.
Publicado: (2011) -
HnRNP L represses cryptic exons
por: McClory, Sean P., et al.
Publicado: (2018) -
HnRNP Pathologies in Frontotemporal Lobar Degeneration
por: Jiang, Xinwa, et al.
Publicado: (2023) -
The Eµ-hnRNP K Murine Model of Lymphoma: Novel Insights into the Role of hnRNP K in B-Cell Malignancies
por: Malaney, Prerna, et al.
Publicado: (2021)